Welcome to Novo Nordisk Science Hub
The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Dr. A.G. (Onno) Holleboom MD PhD is an internist registered in Vascular Medicine and Endocrinology, faculty member of the Department of Vascular Medicine and Assistant Professor at Amsterdam UMC. He heads a multidisciplinary outpatient clinic for NAFLD together with hepatology and including clinical trials. Within the NAFLD-NL consortium and supported by the Dutch MLDS gastroenterology and hepatology foundation, his team investigates and implements care paths for NAFLD together with LUMC and Radboud MC. He participates in LITMUS, will participate in the new Grip on NASH consortium, has co-authored the Dutch NAFLD-NASH guideline and is on the Delphi panel for the revised EASL-EASD-EASO guideline. Together with prof. Max Nieuwdorp, he runs a research group with 5 PhD candidates focussing on genetic and gut microbial drivers of NAFLD in three cohort studies, as well as more fundamental work on pathways around lipophagy and liver sinusoidal endothelium. He has published 73 peer-reviewed articles, including in Circulation and Cell Metabolism and received various prestigious grants, a.o. from The Netherlands Organization for Scientific Research and the Amsterdam UMC Fellowship.
Lise Lotte Gluud
University of Copenhagen, Copenhagen, Denmark
Prof. Lise L Gluud is a consultant Gastroenterologist and Professor of gastroenterology and hepatology, a member of the steering committee at Centre for Liver Disease in Copenhagen (CLIC) and the Centre for Obesity at Amager and Hvidovre Hospital. Her main research areas include lifestyle associated liver diseases focusing on non-alcoholic steatohepatitis as well as cirrhosis-related complications and clinical as well as pathophysiological studies with 162 Medline Indexed publications and a H index of 66. Other interest areas include inflammatory and metabolic complications associated with pancreatitis. She has Qualifications include: Specially Appointed Named Person at the Faculty of Health and Medical Sciences, University of Copenhagen, Member of the National Committee on Health Research Ethics; Chairman of the National Clinical Guideline for the Management of patients with NAFLD; Chairman of the Danish Association of Gastroenterology and Hepatology (DSGH) Research Committee; Plos ONE Section Editor; and Editor Cochrane Hepato-Biliary Group.
Read full bio
Elisabetta Bugianesi
Division of Gastroenterology, Department of Medical Sciences, University of Torino, Torino, Italy
Prof. Bugianesi is a clinician and scientist, internationally acknowledged expert on Non-Alcoholic Fatty Liver Disease (NAFLD/NASH) with 20 years of experience in the field. Her clinical practice is based in the Division of Gastroenterology at the AOU Città della Scienza e della Salute di Torino. She leads the regional NAFLD specialist clinical service based at the San Giovanni Antica Sede Hospital, in Torino. She has made a particular impact with work describing the metabolic mechanisms related to the onset and progression of liver damage and its links with the metabolic syndrome and its components, the natural history of the disease, including the first demonstration of HCC as a complication, the development of non-invasive markers of fibrosis and the involvement in several trials for the treatment of NAFLD. Her post-graduate training included a PhD fellowship in Hepatology at Case Western Reserve University in USA, where she became expert in the use of stable isotopes to study in vivo metabolism.
Read full bio